“Natural” is not synonymous with “Safe”: Toxicity of natural products alone and in combination with pharmaceutical agents
- 18 March 2020
- journal article
- research article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 113, 104642
- https://doi.org/10.1016/j.yrtph.2020.104642
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (U54AT008909, R01GM121354)
This publication has 45 references indexed in Scilit:
- Herb–Drug Interactions: Challenges and Opportunities for Improved PredictionsDrug Metabolism and Disposition, 2013
- The evolution and comparative neurobiology of endocannabinoid signallingPhilosophical Transactions B, 2012
- Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506)International Journal of Pharmaceutics, 2010
- Sandwich-cultured hepatocytes: anin vitromodel to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicityDrug Metabolism Reviews, 2010
- Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteersBritish Journal of Clinical Pharmacology, 2009
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007
- Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity StudiesDrug Metabolism Reviews, 2007
- ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactionsDrug Discovery Today: Technologies, 2004
- IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACTDrug Metabolism and Disposition, 2004
- Characterization of cannabidiol-mediated cytochrome P450 inactivationBiochemical Pharmacology, 1993